Table 2.
Therapeutic modulators of PP2A activity.
| PP2A modulators | Target | Phosphatase activity | Ongoing Clinical Trials | Application | References |
|---|---|---|---|---|---|
| Ceramide | SET | Activating | NCT04716452: Phase I | Acute Myeloid Leukemia | (150,151,200) |
| FTY720 (Fingolimoid) | SET | Activating | NCT03941743: Phase I | Breast Cancer | (201,202) |
| FDA Approved | Multiple Myeloma | ||||
| FDA Approved | Mantle Cell Lymphoma | ||||
| NCT05137860: Phase IV | Acute Lymphoblastic Leukemia | ||||
| Bortezomib | CIP2A | Activating | NCT01371981: Phase III | Acute Myeloid Leukemia | (203–205) |
| NCT03509246: Phase II | Ovarian Cancer | ||||
| NCT01142401: Phase II | Breast Cancer | ||||
| NCT00479128: Phase I | Urothelial Cancer | ||||
| LB100 | PP2Ac | Inhibiting | NCT03027388: Phase II | Glioblastoma | (174,206) |
| NCT04560972: Phase I | Small Cell Lung Cancer | ||||
| OP499 | SET | Activating | Pre-clinical | (50,201,207) | |
| iHAP1 | PP2A-B56ϵ | Activating | Pre-clinical | (169) | |
| DT061 | PP2A-B56α, PP2A-B55α | Activating | Pre-clinical | (169–171,173,208,209) |